XNCR - Xencor, Inc.
| Previous Close | 32.25 |
| Open | 31.10 |
| Bid | 31.70 x 1100 |
| Ask | 32.00 x 1200 |
| Day's Range | 29.95 - 31.87 |
| 52 Week Range | 27.21 - 48.38 |
| Volume | 713,538 |
| Avg. Volume | 192,477 |
| Market Cap | 1.779B |
| Beta (3Y Monthly) | 1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.07 |
| Earnings Date | Feb 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.14 |
- Zacks•13 hours ago
Strong Friday Close Secures a 9th Week in the Green
Strong Friday Close Secures a 9th Week in the Green
- PR Newswire•4 days ago
Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045
MONROVIA, Calif., Feb. 20, 2019 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase 1 study of XmAb14045, a CD123 x CD3 bispecific antibody molecule being evaluated in patients with relapsed or refractory acute myeloid leukemia and other CD123-expressing hematologic malignancies. No new patients will be allowed to enroll in the study until the partial clinical hold is lifted by the FDA.
- PR Newswire•5 days ago
Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019
MONROVIA, Calif. , Feb. 19, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
- Markit•16 days ago
See what the IHS Markit Score report has to say about Xencor Inc.
Xencor Inc NASDAQ NMS:XNCRView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for XNCR with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding XNCR totaled $2.56 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- PR Newswire•17 days ago
Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif. , Feb. 7, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
- PR Newswire•19 days ago
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
MONROVIA, Calif., Feb. 5, 2019 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, today announced it has entered into a research and license agreement with Genentech, a member of the Roche Group, to develop and commercialize novel IL-15 cytokine therapeutics, including XmAb®24306. XmAb24306 is an IL-15/IL-15Rα cytokine complex engineered with Xencor's bispecific Fc domain and Xtend™ Fc technology and is Xencor's most advanced preclinical cytokine program.
- GlobeNewswire•27 days ago
Report: Developing Opportunities within ONEOK, Alaska Air Group, Comcast, Mack-Cali Realty, Vistra Energy, and Xencor — Future Expectations, Projections Moving into 2019
NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•last month
Have Insiders Been Selling Xencor, Inc. (NASDAQ:XNCR) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
- PR Newswire•2 months ago
Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody
MONROVIA, Calif., Jan. 7, 2019 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease and cancer, today announced it will regain rights to develop and commercialize XmAb13676, a CD20 x CD3 bispecific antibody, from Novartis effective June 20, 2019, due to strategic pipeline reprioritization by Novartis. Xencor granted Novartis co-development and ex-U.S. commercial rights in June 2016 through a collaboration and license agreement to develop and commercialize novel bispecific antibodies, including XmAb13676 and XmAb14045, and to access Xencor's XmAb® bispecific Fc and other Fc technologies.
- Simply Wall St.•3 months ago
Is Xencor Inc (NASDAQ:XNCR) A Financially Strong Company?
Mid-caps stocks, like Xencor Inc (NASDAQ:XNCR) with a market capitalization of US$2.4b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. Read More...
- PR Newswire•3 months ago
Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
MONROVIA, Calif., Dec. 3, 2018 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced initial data from its ongoing Phase 1 dose-escalation study of XmAb®14045, a CD123 x CD3 bispecific antibody, in patients with relapsed/refractory acute myeloid leukemia (AML). The data were presented in an oral session at the 2018 American Society of Hematology (ASH) Annual Meeting by Farhad Ravandi, M.D., Professor of Medicine and Chief of the Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas – MD Anderson Cancer Center. 66 patients with relapsed/refractory AML received XmAb14045.
- PR Newswire•3 months ago
Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference
MONROVIA, Calif. , Nov. 20, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
- PR Newswire•4 months ago
Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors
MONROVIA, Calif., Nov. 8, 2018 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced the appointment of Ellen G. Feigal, M.D., to its board of directors. Dr. Feigal is currently a partner at NDA Partners, a strategy consulting firm, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. "Dr. Feigal's exceptional career as an oncologist in clinical development spans 30 years across leadership roles in industry, academia, public service and nonprofits, and she has accrued a unique perspective from this wealth of experience," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of XNCR earnings conference call or presentation 5-Nov-18 9:30pm GMT
Q3 2018 Xencor Inc Earnings Call
- Associated Press•4 months ago
Xencor: 3Q Earnings Snapshot
The Monrovia, California-based company said it had net income of 5 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- PR Newswire•4 months ago
Xencor Reports Third Quarter 2018 Financial Results
- Initial Data from Phase 1 Dose-Escalation Study of XmAb®14045 in Acute Myeloid Leukemia (AML) to Be Presented at 2018 ASH Annual Meeting - - Plan to Initiate Phase 3 Study of XmAb®5871 in IgG4-Related ...
- PR Newswire•4 months ago
Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
MONROVIA, Calif., Nov. 1, 2018 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced that initial data from its ongoing Phase 1 dose-escalation study of XmAb®14045, a CD123 x CD3 bispecific antibody, in patients with relapsed/refractory acute myeloid leukemia (AML) will be presented in an oral session at the 2018 American Society of Hematology (ASH) Annual Meeting on Monday, December 3, 2018. At data cut off on June 27, 2018, 63 patients with relapsed/refractory AML and one patient with B cell acute lymphoblastic leukemia had received XmAb®14045.
- Zacks•4 months ago
Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire•4 months ago
Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018
MONROVIA, Calif. , Oct. 29, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
